SCHEMBL6313640

SCHEMBL6313640

CCCCCCCCC1Cc2c(cc(C(C)(C)C)c(O)c2C(C)(C)C)O1

nearest known ligand 0.39

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 2/20 0.39
▸ PPARG P37231 2/20 0.36
▸ SIRT2 Q8IXJ6 7/20 0.35
▸ SMPD1 P17405 1/20 0.35
▸ GRM2 Q14416 2/20 0.34
▸ CYP1A2 P05177 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ EPHX1 P07099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6306075 0.81 CA2 (0.33) CYP1A2ALDH1A1
SCHEMBL6768465 0.80 DRD1 (0.46) DRD1PPARGSIRT2SMPD1GRM2
SCHEMBL6765211 0.78 SIRT2 (0.40) DRD1PPARGSIRT2SMPD1GRM2
SCHEMBL6313866 0.74 POLB (0.38) CYP1A2ALDH1A1
SCHEMBL7530258 0.74 NR5A2 (0.31) DRD1
SCHEMBL6130782 0.73 CA2 (0.35) DRD1CYP1A2ALDH1A1
SCHEMBL9846905 0.72 BACE1 (0.43) DRD1ALDH1A1
SCHEMBL5471648 0.71 PTPN1 (0.37) SIRT2
SCHEMBL5474046 0.71 PTPN1 (0.37) SIRT2
SCHEMBL5474064 0.71 PTPN1 (0.37) SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050159476-A1 Pharmaceutical composition for preventing or treating respiratory disease CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-07-21 — — US disclosed
US-20030195246-A1 Seamless soft capsule preparations containing dihydrobenzofuran derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-10-16 — — US disclosed
EP-1314424-A1 SEAMLESS SOFT CAPSULE PREPARATIONS CONTAINING DIHYDROBENZOFURAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-05-28 — — EP disclosed
US-6440999-B1 Intimal thickening inhibitory agent CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-27 — — US disclosed
US-6417225-B1 HYDROQUINONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-07-09 — — US disclosed
US-6156793-A Prophylactic/therapeutic agents for atherosclerosis CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-12-05 — — US disclosed
US-6133279-A A 2,6-DI-T-BUTYLPHENOL DERIVATIVE FOR RENAL DISEASES, E.G., CHRONIC RENAL FAILURE, DIABETIC NEPHROPATHY GLOMERULAR NEPHRITIS, IMMUNOCOMPLEX NEPHRITIS AND ACUTE RENAL FAILURE; CYTOPROTECTIVE AGENT THAT INHIBITS THE LIPID PEROXIDATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-10-17 — — US disclosed
US-6103753-A ADMINISTERING TO A PATIENT FOR INHIBITING THICKENING OF VASCULAR STENOSIS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, A 2,6-DI-T-BUTYLPHENOL DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-08-15 — — US disclosed
EP-0982029-A1 PREVENTIVES/REMEDIES FOR ARTERIOSCLEROSIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-03-01 — — EP disclosed
EP-0950405-A1 REMEDIES FOR RENAL DISEASES AND ORGAN-PRESERVING AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1999-10-20 — — EP disclosed
EP-0665208-B1 4-ALKOXY-2,6-DI-t-BUTYLPHENOL DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 1999-01-13 — — EP disclosed
EP-0868913-A1 INTIMAL THICKENING INHIBITOR Chugai Seiyaku Kabushiki Kaisha (JP) 1998-10-07 — — EP disclosed
US-5663373-A ANTIISCHEMIC AGENTS AND ANTIOXIDANTS FORMED IN MULTISTAGE REACTION WITH GRIGNARD REAGENT WITH ALDEHYDE, DISSOLVING, ACIDIFICATION, DEPROTECTION AND CYCLIZATION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1997-09-02 — — US disclosed
US-5606089-A ANTIISCHEMIC AGENTS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1997-02-25 — — US disclosed
US-5574178-A CHEMICAL INTERMEDIATES FOR OXIDATION RESISTANCE AND ANTIISCHEMIC AGENTS FORMED BY MULTISTAGE CYCLIZATION OF ALDEHYDE-ALCOHOL CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1996-11-12 — — US disclosed
EP-0665208-A1 4-ALKOXY-2,6-DI-t-BUTYLPHENOL DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 1995-08-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159476-A1 Pharmaceutical composition for preventing or treating respiratory disease CFTR, CMA1, SLC5A1 DRD1 2625/4885PPARG 383/4885SIRT2 1321/4885
US-20030195246-A1 Seamless soft capsule preparations containing dihydrobenzofuran derivatives CYP2D6, CYP2F1, SULT2A1 DRD1 436/4885PPARG 1410/4885SIRT2 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback